Blueprint Medicines Corporation
blueprintmedicines.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
32
Active
8
Phase 3
2
Total enrollment
5,322
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Avapritinib | — | 12 | |||||
| Elenestinib | — | — | — | — | 2 | ||
| BLU-808 | — | — | — | — | 3 | ||
| BLU-924 | — | — | — | — | — | 1 |
Next readouts
- 2026-12-31
- 2027-06-23
- 2027-12-31
- 2028-12-01
- 2029-09
- 2032-09-30
Top conditions
- Indolent Systemic Mastocytosis4
- Carcinoma, Non-Small-Cell Lung4
- Respiratory Tract Neoplasms4
- Neoplasms4
- Neoplasms by Site4
- Lung Diseases4
- Carcinoma, Bronchogenic4
- Carcinoma4
Frequently asked questions about Blueprint Medicines Corporation
- How many clinical trials does Blueprint Medicines Corporation have on ClinicalTrials.gov?
- Blueprint Medicines Corporation is listed as the lead sponsor on 32 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Blueprint Medicines Corporation's trials are in Phase 3?
- 2 of Blueprint Medicines Corporation's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Blueprint Medicines Corporation focus on?
- Blueprint Medicines Corporation's most-studied conditions on ClinicalTrials.gov are Indolent Systemic Mastocytosis, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site.
- When are Blueprint Medicines Corporation's next clinical trial readouts?
- Blueprint Medicines Corporation has 6 upcoming primary-completion readouts tracked here; the soonest is “Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)”, expected around 2026-12-31.